Zydus Cadila secures USFDA nod for Droxidopa Capsules to treat low blood pressure
Ahmedabad: Pharma major, Zydus Cadila, today announced that the company has received final approval from the USFDA to market Droxidopa Capsules, 100 mg, 200 mg, and 300 mg (US RLD: Northera Capsules).
Droxidopa works by constricting (narrowing) the blood vessels and increasing blood pressure. It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.
It is indicated for use in people with conditions of the nervous system that can cause low blood pressure (such as Parkinson's disease, multiple system atrophy, autonomic failure, and others).
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 312 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila net profit rises 41 percent to Rs 527 crore in Q3
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.